In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients

A. Cortelezzi, B. Sarina, C. Cattaneo, M. Pomati, I. Silvestris, D. Soligo, R. Calori, M. Di Stefano, C. Hu, M. Monza, L. Radelli, A. T. Maiolo

Research output: Contribution to journalArticle

Abstract

To evaluate the clinical usefulness of IL-2 in myelodysplastic syndromes (MDS) the in vitro effects of interleukin-2 (IL-2) on blast cell proliferation, clonogenic activity, cytokine release and cell mediated cytotoxicity were examined in 49 MDS patients. Morphological analyses of bone marrow (BM) cytospin preparations showed a significant decrease in the number of blast cells in MDS after incubation with IL-2. Incubation of bone marrow mononuclear cells (BMMNCs) with IL-2 induced a significant increase in the number of CFU-GM in comparison with untreated controls, γ-IFN and GM-CSF, but not α-TNF were found to be released in significant amounts by the BMMNCs cultured with IL-2. No significant differences in the surface phenotypes of fresh lymphocytes were observed between the normal and MDS subjects. After incubation with IL-2, we observed a significant increase in the number of CD3-/CD56+ cells in both normal and MDS subjects. Peripheral blood (PB) and BM NK activity against K562 was significantly greater in MDS after stimulation with IL-2. These data suggest the clinical usefulness of IL-2 in a large subgroup of patients as it may reduce the percentage of blasts and increase clonogenic capacity and cell-mediated cytotoxicity.

Original languageEnglish
Pages (from-to)1181-1189
Number of pages9
JournalLeukemia
Volume10
Issue number7
Publication statusPublished - Jul 1996

Fingerprint

Myelodysplastic Syndromes
Interleukin-2
Bone Marrow
Cell Proliferation
Cytokines
Bone Marrow Cells
Granulocyte-Macrophage Progenitor Cells
In Vitro Techniques
Granulocyte-Macrophage Colony-Stimulating Factor
Cell Count
Lymphocytes
Phenotype

Keywords

  • Clonogenic activity
  • Cytokines
  • Interleukin-2
  • Myelodysplastic syndromes

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients. / Cortelezzi, A.; Sarina, B.; Cattaneo, C.; Pomati, M.; Silvestris, I.; Soligo, D.; Calori, R.; Di Stefano, M.; Hu, C.; Monza, M.; Radelli, L.; Maiolo, A. T.

In: Leukemia, Vol. 10, No. 7, 07.1996, p. 1181-1189.

Research output: Contribution to journalArticle

Cortelezzi, A, Sarina, B, Cattaneo, C, Pomati, M, Silvestris, I, Soligo, D, Calori, R, Di Stefano, M, Hu, C, Monza, M, Radelli, L & Maiolo, AT 1996, 'In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients', Leukemia, vol. 10, no. 7, pp. 1181-1189.
Cortelezzi, A. ; Sarina, B. ; Cattaneo, C. ; Pomati, M. ; Silvestris, I. ; Soligo, D. ; Calori, R. ; Di Stefano, M. ; Hu, C. ; Monza, M. ; Radelli, L. ; Maiolo, A. T. / In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients. In: Leukemia. 1996 ; Vol. 10, No. 7. pp. 1181-1189.
@article{5dd5365aaefb4a0c96785cfca37eed44,
title = "In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients",
abstract = "To evaluate the clinical usefulness of IL-2 in myelodysplastic syndromes (MDS) the in vitro effects of interleukin-2 (IL-2) on blast cell proliferation, clonogenic activity, cytokine release and cell mediated cytotoxicity were examined in 49 MDS patients. Morphological analyses of bone marrow (BM) cytospin preparations showed a significant decrease in the number of blast cells in MDS after incubation with IL-2. Incubation of bone marrow mononuclear cells (BMMNCs) with IL-2 induced a significant increase in the number of CFU-GM in comparison with untreated controls, γ-IFN and GM-CSF, but not α-TNF were found to be released in significant amounts by the BMMNCs cultured with IL-2. No significant differences in the surface phenotypes of fresh lymphocytes were observed between the normal and MDS subjects. After incubation with IL-2, we observed a significant increase in the number of CD3-/CD56+ cells in both normal and MDS subjects. Peripheral blood (PB) and BM NK activity against K562 was significantly greater in MDS after stimulation with IL-2. These data suggest the clinical usefulness of IL-2 in a large subgroup of patients as it may reduce the percentage of blasts and increase clonogenic capacity and cell-mediated cytotoxicity.",
keywords = "Clonogenic activity, Cytokines, Interleukin-2, Myelodysplastic syndromes",
author = "A. Cortelezzi and B. Sarina and C. Cattaneo and M. Pomati and I. Silvestris and D. Soligo and R. Calori and {Di Stefano}, M. and C. Hu and M. Monza and L. Radelli and Maiolo, {A. T.}",
year = "1996",
month = "7",
language = "English",
volume = "10",
pages = "1181--1189",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - In vitro effects of IL-2 on NK-activity, clonogenic potential, blast cell proliferation and cytokine release of MDS bone marrow patients

AU - Cortelezzi, A.

AU - Sarina, B.

AU - Cattaneo, C.

AU - Pomati, M.

AU - Silvestris, I.

AU - Soligo, D.

AU - Calori, R.

AU - Di Stefano, M.

AU - Hu, C.

AU - Monza, M.

AU - Radelli, L.

AU - Maiolo, A. T.

PY - 1996/7

Y1 - 1996/7

N2 - To evaluate the clinical usefulness of IL-2 in myelodysplastic syndromes (MDS) the in vitro effects of interleukin-2 (IL-2) on blast cell proliferation, clonogenic activity, cytokine release and cell mediated cytotoxicity were examined in 49 MDS patients. Morphological analyses of bone marrow (BM) cytospin preparations showed a significant decrease in the number of blast cells in MDS after incubation with IL-2. Incubation of bone marrow mononuclear cells (BMMNCs) with IL-2 induced a significant increase in the number of CFU-GM in comparison with untreated controls, γ-IFN and GM-CSF, but not α-TNF were found to be released in significant amounts by the BMMNCs cultured with IL-2. No significant differences in the surface phenotypes of fresh lymphocytes were observed between the normal and MDS subjects. After incubation with IL-2, we observed a significant increase in the number of CD3-/CD56+ cells in both normal and MDS subjects. Peripheral blood (PB) and BM NK activity against K562 was significantly greater in MDS after stimulation with IL-2. These data suggest the clinical usefulness of IL-2 in a large subgroup of patients as it may reduce the percentage of blasts and increase clonogenic capacity and cell-mediated cytotoxicity.

AB - To evaluate the clinical usefulness of IL-2 in myelodysplastic syndromes (MDS) the in vitro effects of interleukin-2 (IL-2) on blast cell proliferation, clonogenic activity, cytokine release and cell mediated cytotoxicity were examined in 49 MDS patients. Morphological analyses of bone marrow (BM) cytospin preparations showed a significant decrease in the number of blast cells in MDS after incubation with IL-2. Incubation of bone marrow mononuclear cells (BMMNCs) with IL-2 induced a significant increase in the number of CFU-GM in comparison with untreated controls, γ-IFN and GM-CSF, but not α-TNF were found to be released in significant amounts by the BMMNCs cultured with IL-2. No significant differences in the surface phenotypes of fresh lymphocytes were observed between the normal and MDS subjects. After incubation with IL-2, we observed a significant increase in the number of CD3-/CD56+ cells in both normal and MDS subjects. Peripheral blood (PB) and BM NK activity against K562 was significantly greater in MDS after stimulation with IL-2. These data suggest the clinical usefulness of IL-2 in a large subgroup of patients as it may reduce the percentage of blasts and increase clonogenic capacity and cell-mediated cytotoxicity.

KW - Clonogenic activity

KW - Cytokines

KW - Interleukin-2

KW - Myelodysplastic syndromes

UR - http://www.scopus.com/inward/record.url?scp=9344259102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9344259102&partnerID=8YFLogxK

M3 - Article

C2 - 8684000

AN - SCOPUS:9344259102

VL - 10

SP - 1181

EP - 1189

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -